A 25-year-old male developed lymphoid blast crisis (BC) of chronic myelogenous leukemia (CML) more than 11 years after receiving an allogeneic bone marrow transplant (alloBMT) for CML with myeloid BC at presentation from his HLA-identical brother. The lymphoid BC of CML probably occurred without a preceding chronic phase of CML. This case illustrates the difficulties involved in determining the appropriate length of followup after alloBMT.
The incidence of recurrent leukemia more than 10 years after allogeneic bone marrow transplant (alloBMT) is very low. The pathogenesis of late relapse after alloBMT remains unknown. Cytogenetic evolution or oncogene alternations may be related to a failure of the graftversus-leukemia (GVL) effect. An early diagnosis of late relapse and countermeasures such as donor leukocyte infusion (DLI) are required. We describe a patient who relapsed with lymphoid blast crisis (BC) of chronic myelogenous leukemia (CML) more than 11 years after alloBMT for CML in myeloid BC at presentation.
Case report
A 12-year-old male was admitted to our hospital with nasal bleeding in March 1987. Peripheral blood analysis revealed: hemoglobin, 11.1 g/dl; platelet count, 111 Â 10 9 /l and white blood cell count, 150 Â 10 9 /l. Bone marrow findings supported a diagnosis of myeloid BC of CML (Table 1) . Treatment with busulfan and 6-mercaptopurine brought him into chronic phase (CP) of CML. In December 1988, he received an alloBMT for CP CML from his HLAidentical brother. The conditioning regimen consisted of busulfan 16 mg/kg orally and melphalan 180 mg/m 2 intravenously. Methotrexate for prophylaxis of graft-versushost disease was discontinued by day 53 and the patient was followed for 4 years post-alloBMT.
The patient had been well for over 11 years until March 2000, when he was readmitted to our hospital with nasal bleeding. Laboratory findings were as follows: white blood cell count, 3.7 Â 10 9 /l with 10% blasts; hemoglobin, 12.3 g/ dl and platelet count, 3.0 Â 10 9 /l. Terminal deoxynucleotidyl transferase was negative. Bone marrow findings suggested recurrent CML in lymphoid BC or de novo acute lymphoblastic leukemia (ALL) ( Table 1) . A FISH study was 71.6% positive (normal range o4.3%) for the bcr-abl fusion transcript. Both major and minor bcr-abl fusion transcripts were detected by reverse-transcription polymerase chain reaction (RT-PCR). The patient achieved complete remission (CR) on day 27 after the first half of reinduction chemotherapy, consisting of enocitabine, daunorubicin, 6-mercaptopurine, adriamycin, prednisolone, and vincristine. Cytogenetic analysis revealed that the Philadelphia (Ph 1 ) chromosome had disappeared. The second half of reinduction chemotherapy, consisting of asparaginase and cyclophosphamide, was started from day 30. On day 43, the bcr-abl fusion transcript was 2.6% positive according to the FISH study, but obviously positive by RT-PCR.
A short tandem repeat (STR) sequence marker on chromosome 18 that differed between donor and recipient was used to quantify mixed chimerism (Figure 1a-d) . The ratio of recipient to donor cells calculated from electropherograms obtained from bone marrow smears at relapse in lymphoid BC of CML was 32%, suggesting that the leukemia cell was induced by host cell (Figure 1c) . The ratio of recipient to donor cells in the peripheral blood on day 9 after reinduction chemotherapy, when blast cells had disappeared, was 0 with 90% confidence (Figure 1d ).
The patient relapsed after the second course of consolidation chemotherapy. In December 2000, he received a second alloBMT from an HLA-identical unrelated donor, but then died of pneumonia and sepsis on day 4.
Discussion
In diagnosing leukemia after alloBMT, the origin of the leukemic cells has to be determined in order to select an appropriate therapeutic approach. The relative incidence of donor cell leukemia (DCL) and secondary leukemia increases with time after alloBMT. Five patients are considered to have developed DCL after alloBMT for CML. 1 The leukemia (March 2000) was confirmed to be host cell leukemia by using STR sequences markers. A few primary leukemic cells that survived conditioning chemotherapy and escaped the GVL effect might have induced leukemic relapse, although chromosomal analysis did not identify any additional cytogenetic evolution such as trisomy 8 or an extra Ph 1 chromosome. An immunophenotypic switch of the blast cells from myeloid at onset to lymphoid lineage at relapse postalloBMT might be related to oncogene alternations such as homozygous deletions of p16 tumor suppressor gene on chromosome 9p21 associated with lymphoid BC of CML. 2, 3 Electrophoresis identified fewer minor than major bcrabl fusion transcripts at the time of lymphoid BC of CML. Although the p190 bcr-abl fusion transcript may correlate with transformation into BC of CML, 4 Morgan et al 5 described that its acquisition does not play a significant role in the generation of BC of CML. Lichty et al 6 found that 35 of 67 patients with CML coexpressed p190 and p210, possibly because of alternative splicing. van Rhee et al 7 frequently found p190 bcr-abl fusion transcripts at a low level in leukemias positive for p210 bcr-abl fusion transcripts including ALL. Therefore, the presence of this transcript is probably of no pathogenetic significance. Besides these hypotheses, the sensitivity of bcr-abl-positive stem cells to conditioning chemotherapy or the GVL effect have to be studied.
This case illustrates the difficulties involved in determining the appropriate length of follow up after alloBMT. Radich et al 8 described that PCR assay of the bcr-abl fusion transcript 6-12 months after BMT for CML is an independent predictor of subsequent relapse. However, minimal residual disease (MRD) in CML patients after alloBMT is not necessarily associated with relapse. van Rhee et al 9 reported that two of the 19 patients with CML in first CP transplanted from HLA-identical sibling donors in remission for over 10 years had molecular evidence of persisting leukemic cells. The GVL effect may suppress persisting leukemic clones. A few CML patients with MRD will probably proceed to late relapse. To our knowledge, the longest period from alloBMT for CML to relapse is 14 Leukemia 11 years after alloBMT K Fukuno et al years. 10 CML patients who had increasing or persistently high bcr-abl fusion transcripts after alloBMT were likely to relapse. 11 To identify patients at high risk of relapse in whom an established intervention such as DLI may be able to avert relapse, 12 persisting or recurrent evidence of leukemia at the molecular level should be monitored by quantitative PCR for the bcr-abl fusion transcript.
Although the patient had not been followed up between 4 and 11 years post-alloBMT, the lymphoid BC of CML after first alloBMT probably occurred without a preceding CP since the ratio of recipient to donor cells in quantitative analysis of mixed chimerism using STR sequences markers on day 9 after reinduction chemotherapy was already 0%. Further studies are required to elucidate the pathogenesis of late relapse after alloBMT.
